Bristol Myers Squibb stock on a thin disclosure day

By Christina Vaughn, Background & Management desk. Reviewed on July 7, 2026 at 6:42 p.m. ET.

Bristol Myers Squibb (ISIN US0897961004) is a large U.S. drugmaker with a New York Stock Exchange listing and a portfolio centered on oncology, immunology, cardiovascular medicine, and cell therapy. For investors, the main frame remains the company's mix of marketed products, late-stage pipeline assets, and capital allocation.

Business mix

The company generates revenue from a broad set of prescription medicines rather than a single product line, which gives the stock a different profile from more concentrated biotech names. Its commercial mix includes therapies used in cancer, blood disorders, and chronic disease treatment.

Market context

As a member of the S&P 500, Bristol Myers Squibb also sits inside the U.S. large-cap health-care universe that institutional investors use as a benchmark for defensive exposure. That index membership matters because passive flows and relative performance screens often shape trading in names like this.

Products and pipeline

Key branded medicines include Opdivo, Eliquis, Revlimid, and Orencia, while the development pipeline continues to matter for medium-term sentiment. In this group, the market usually watches whether new data can offset patent pressure and slower growth in older franchises.

Stock level

Bristol Myers Squibb shares are priced at $0.00 as of July 7, 2026, 6:42 p.m. ET.

This article was generated automatically and technically reviewed before publication. Market prices, analyst data and company information are provided without warranty and may change at short notice. This content is for informational purposes only and is not investment, financial, legal or tax advice. It is not a recommendation to buy or sell any security. Investing in securities involves risk, including the possible loss of principal.